IN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation

Reuters

11/24

IN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation

IN8BIO Inc. has released a corporate presentation highlighting recent developments across its pipeline of gamma-delta T cell therapies. The company provided updates on its DeltEx platform, with clinical milestones anticipated for programs in acute myeloid leukemia (AML) and glioblastoma (GBM). For AML, IN8BIO plans to complete enrollment and dosing for additional patients in an expansion cohort, with ongoing clinical updates expected in 2026. In GBM, the company aims to report long-term overall survival data and Phase 2 trial results at upcoming scientific meetings. Efforts in autoimmune indications remain on hold, with potential advancement to IND-enabling studies in 2026. Additional details regarding program prioritization are available in the company's recent SEC filings. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2585462068"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2585462068\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2585462068?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585462068","market":"us","top_or_hot":-1,"title":"IN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IN8BIO Inc. has released a corporate presentation highlighting recent developments across its pipeline of gamma-delta T cell therapies. The company provided updates on its DeltEx platform, with clinical milestones anticipated for programs in acute myeloid leukemia (AML) and glioblastoma (GBM). For AML, IN8BIO plans to complete enrollment and dosing for additional patients in an expansion cohort, with ongoing clinical updates expected in 2026. In GBM, the company aims to report long-term overall survival data and Phase 2 trial results at upcoming scientific meetings. Efforts in autoimmune indications remain on hold, with potential advancement to IND-enabling studies in 2026. Additional details regarding program prioritization are available in the company's recent SEC filings. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-24 21:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IN8BIO Inc. has released a corporate presentation highlighting recent developments across its pipeline of gamma-delta T cell therapies. The company provided updates on its DeltEx platform, with clinical milestones anticipated for programs in acute myeloid leukemia (AML) and glioblastoma (GBM). For AML, IN8BIO plans to complete enrollment and dosing for additional patients in an expansion cohort, with ongoing clinical updates expected in 2026. In GBM, the company aims to report long-term overall survival data and Phase 2 trial results at upcoming scientific meetings. Efforts in autoimmune indications remain on hold, with potential advancement to IND-enabling studies in 2026. Additional details regarding program prioritization are available in the company's recent SEC filings. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INAB","symbol_name":"IN8bio, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL1wB41y:1","article_id":"2585462068","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585462068","pubTimestamp":1763990363,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IN8BIO Inc. has released a corporate presentation highlighting recent developments across its pipeline of gamma-delta T cell therapies. The company provided updates on its DeltEx platform, with clinical milestones anticipated for programs in acute myeloid leukemia  and glioblastoma . For AML, IN8BIO plans to complete enrollment and dosing for additional patients in an expansion cohort, with ongoing clinical updates expected in 2026. In GBM, the company aims to report long-term overall survival data and Phase 2 trial results at upcoming scientific meetings. Efforts in autoimmune indications remain on hold, with potential advancement to IND-enabling studies in 2026. Additional details regarding program prioritization are available in the company's recent SEC filings. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INAB":"IN8bio, Inc.","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"IN8BIO在新的公司演示中展示了γ-δ T细胞疗法的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INAB":0.9},"content_text":"IN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation\n    \n\n        IN8BIO Inc. has released a corporate presentation highlighting recent developments across its pipeline of gamma-delta T cell therapies. The company provided updates on its DeltEx platform, with clinical milestones anticipated for programs in acute myeloid leukemia (AML) and glioblastoma (GBM). For AML, IN8BIO plans to complete enrollment and dosing for additional patients in an expansion cohort, with ongoing clinical updates expected in 2026. In GBM, the company aims to report long-term overall survival data and Phase 2 trial results at upcoming scientific meetings. Efforts in autoimmune indications remain on hold, with potential advancement to IND-enabling studies in 2026. Additional details regarding program prioritization are available in the company's recent SEC filings. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}